alexsl/iStock via Getty Images

Landmark Health (NASDAQ:HLTH -18.2%) recorded its second-worst intraday decline for this month to hit a 52-week low as healthcare sector and COVID-19 test makers underperform the wider market on Wednesday.

Other notable declines include Abbott Laboratories (ABT -4.0%), Bio-Rad Laboratories (BIO -3.9%) and PerkinElmer (ICP -3.8%).

Cue Health (HLTH) markets an FDA-cleared COVID-19 PCR test kit for use at home, in medical offices, and in non-medical practices.

The company made its public debut last September and shares have fallen more than 50% in the year so far. Leading COVID-19 test developers, Abbott (ABT), Thermo Fisher Scientific (TMO -2.8%) and Quidel (QDEL -1.4%) also declined for the year, while Becton, Dickinson (BDX -1.0%) recorded gains.

The sale comes despite the presence of a fast-spreading subvariant of Omicron, which White House chief medical adviser Dr. Anthony Fauci says could lead to a further spike in COVID-19 cases in the states. -United.

Despite a recent decline in coronavirus infections, the BA.2 subvariant accounted for more than a third of all COVID-19 cases since last week, according to the latest estimates from the Centers for Disease Control and Prevention (CDC) of the United States.